Clozapine blunts N-methyl-D-aspartate antagonist-induced psychosis: a study with ketamine. (Q42547253)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9325559%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

title

Clozapine blunts N-methyl-D-aspartate antagonist-induced psychosis: a study with ketamine (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9325559%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

1 reference

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9325559%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

author name string

A K Malhotra

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9325559%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

C M Adler

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9325559%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

S D Kennison

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9325559%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

D Pickar

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9325559%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

A Breier

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9325559%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

language of work or name

English

0 references

publication date

1 October 1997

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9325559%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

published in

Biological Psychiatry

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9325559%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

volume

42

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9325559%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

issue

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9325559%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

page(s)

664-668

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9325559%20AND%20SRC:MED&resulttype=core&format=json

Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia.

6 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2896%2900546-X

Behavioral effects of phencyclidine and ketamine alone and in combination with other drugs.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2896%2900546-X

Inhibition of mammalian brain acetylcholinesterase by ketamine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2896%2900546-X

Clozapine but not haloperidol antagonizes an MK-801 discriminative stimulus cue.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2896%2900546-X

Actions of clozapine and haloperidol on the extracellular levels of excitatory amino acids in the prefrontal cortex and striatum of conscious rats.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2896%2900546-X

Dose-finding trial of D-cycloserine added to neuroleptics for negative symptoms in schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2896%2900546-X

Amelioration of negative symptoms in schizophrenia by glycine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2896%2900546-X

Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2896%2900546-X

Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2896%2900546-X

Preliminary investigation of high-dose oral glycine on serum levels and negative symptoms in schizophrenia: an open-label trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2896%2900546-X

Anti-glutamatergic effects of clozapine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2896%2900546-X

NMDA receptor function and human cognition: the effects of ketamine in healthy volunteers.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2896%2900546-X

Clinical and biologic response to clozapine in patients with schizophrenia. Crossover comparison with fluphenazine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2896%2900546-X

The interaction of ketamine with the opiate receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2896%2900546-X

Properties of the optical isomers and metabolites of ketamine on the high affinity transport and catabolism of monoamines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2896%2900546-X

Differential effects of chronic antipsychotic drug treatment on extracellular glutamate and dopamine concentrations.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2896%2900546-X

10.1016/S0006-3223(96)00546-X

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9325559%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

1 reference